| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Piperidolate hydrochloride targets muscarinic acetylcholine receptors (mAChRs). As an antimuscarinic agent, it blocks the action of acetylcholine at these receptors. By inhibiting mAChRs in the gastrointestinal and urinary tracts, it helps relax smooth muscles and reduce spasms. This mechanism underlies its use in treating gastrointestinal disorders.
|
|---|---|
| ln Vitro |
Piperidolate hydrochloride inhibits acetylcholine-induced intestinal cramping in vitro. Its activity is confirmed in isolated tissue preparations, where it antagonizes the contractile effects of acetylcholine on smooth muscle. It is used for its antispasmodic and anticholinergic effects.
|
| ln Vivo |
Piperidolate hydrochloride is used in the treatment of gastrointestinal disorders, such as irritable bowel syndrome and peptic ulcers, as well as for pain associated with gastroduodenal ulcer, gastritis, and cholecystitis. Its antispasmodic effects help relieve smooth muscle contractions and associated pain.
|
| Enzyme Assay |
The primary in vitro assay for Piperidolate hydrochloride is a functional assay measuring its ability to inhibit acetylcholine-induced contractions in isolated smooth muscle preparations, such as guinea pig ileum. The compound is added to the tissue bath, and its ability to reduce the contractile response to acetylcholine is measured.
|
| Cell Assay |
Cellular assays for Piperidolate hydrochloride involve treating cells expressing muscarinic receptors with the compound. The inhibition of acetylcholine-induced calcium mobilization or inositol phosphate accumulation is measured. Its effects on smooth muscle cell contraction can be assessed in cell culture models.
|
| Animal Protocol |
In vivo animal experiments for Piperidolate hydrochloride involve administering the compound to animal models of gastrointestinal spasms to assess its antispasmodic efficacy. Its effects on intestinal motility and smooth muscle contractions are evaluated in rats and dogs.
|
| ADME/Pharmacokinetics |
Piperidolate hydrochloride has a molecular weight of 359.89 g/mol and a molecular formula of C21H26ClNO2. Its IUPAC name is (1-ethylpiperidin-3-yl) 2,2-diphenylacetate; hydrochloride. It is a solid.
|
| Toxicity/Toxicokinetics |
Piperidolate hydrochloride is a research compound and is not intended for human use. Its toxicological profile is characteristic of anticholinergic agents. Common adverse effects may include dry mouth, blurred vision, constipation, and urinary retention. Standard safety precautions should be followed when handling.
|
| Additional Infomation |
Piperidolate hydrochloride is a diarylmethane.
Piperidolate hydrochloride is a synthetic antimuscarinic agent with antispasmodic and anticholinergic effects. It is used in research to study muscarinic receptor function and gastrointestinal motility. It is available from various chemical suppliers for research purposes. |
| Molecular Formula |
C21H26CLNO2
|
|---|---|
| Molecular Weight |
359.89
|
| Exact Mass |
359.165
|
| CAS # |
129-77-1
|
| Related CAS # |
Piperidolate;82-98-4
|
| PubChem CID |
8520
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
431.9ºC at 760mmHg
|
| Flash Point |
136ºC
|
| Vapour Pressure |
1.16E-07mmHg at 25°C
|
| LogP |
4.585
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
25
|
| Complexity |
367
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
RBGWCEWDAHDPEH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H25NO2.ClH/c1-2-22-15-9-14-19(16-22)24-21(23)20(17-10-5-3-6-11-17)18-12-7-4-8-13-18;/h3-8,10-13,19-20H,2,9,14-16H2,1H3;1H
|
| Chemical Name |
(1-ethylpiperidin-3-yl) 2,2-diphenylacetate;hydrochloride
|
| Synonyms |
Crapinon; Dactil; Piperidolate hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~50 mg/mL (~138.93 mM)
DMSO : ≥ 32 mg/mL (~88.92 mM) |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7786 mL | 13.8931 mL | 27.7863 mL | |
| 5 mM | 0.5557 mL | 2.7786 mL | 5.5573 mL | |
| 10 mM | 0.2779 mL | 1.3893 mL | 2.7786 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
